Monaco Asset Management SAM Has $1.23 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Monaco Asset Management SAM decreased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 60.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 10,000 shares of the specialty pharmaceutical company’s stock after selling 15,000 shares during the period. Monaco Asset Management SAM’s holdings in Jazz Pharmaceuticals were worth $1,232,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after acquiring an additional 100,112 shares in the last quarter. Centre Asset Management LLC bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at $9,335,000. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at $464,000. Pacer Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after acquiring an additional 278,465 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after acquiring an additional 48,708 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $136.05 on Friday. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The firm has a market cap of $8.26 billion, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a fifty day simple moving average of $129.17 and a two-hundred day simple moving average of $120.60.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on JAZZ shares. Piper Sandler restated an “overweight” rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. HC Wainwright boosted their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $190.53.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,736 shares of company stock worth $4,022,825. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.